



Globular carbosilane dendrimers with mannose groups at the periphery: synthesis, characterization and toxicity in dendritic cells

Paula Ortega^{a,c}, M^a Jesús Serramía^{b,c}, M^a Angeles Muñoz-Fernández^{b,c,*},
F. Javier de la Mata^{a,c,*}, Rafael Gómez^{a,c,*}

^a Departamento de Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871 Alcalá de Henares, Spain

^b Laboratorio de Inmunobiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain

^c Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain

ARTICLE INFO

Article history:

Received 24 November 2009

Received in revised form

25 February 2010

Accepted 26 February 2010

Available online 6 March 2010

Keywords:

Dendrimers

Mannose

Carbosilane

Dendritic cells

ABSTRACT

A synthetic strategy has been developed for the preparation of new globular carbosilane dendrimers with mannose groups at the periphery. It consists of hydrosilylation reaction of allyl tetraacetylmannose with carbosilane dendrimers containing monohydrosilane end groups and the subsequent deacetylation reaction. Evaluation of dendrimer toxicities in dendritic cells by MTT assay were carried out, and evidence a good biocompatibility.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Carbohydrates displayed on the surface of cells play critical roles in cell–cell recognition, adhesion, signaling between cells, and as markers for disease progression, for example, viral and bacterial infections, antibody–antigen interactions, fertilization, and other cell–cell interactions all rely on protein–carbohydrate interactions.¹ The use of dendrimers in carbohydrate chemistry, which has led to a large number of glycodendrimers, is especially attractive.² Dendrimers, macromolecular-branched compounds around an inner core, are gaining popularity as multivalent ligands for the study and modulation of biological events on protein surfaces. In particular, glycodendrimers, and glycopeptides dendrimers³ have found wide use in the study of cellular events mediated by lectins and toxins, and several reviews reflect the latest progress in this field.⁴ Recently, a large number of neo-glycoconjugates carrying different saccharides have been synthesized by several groups and their activities have been evaluated.^{5,6} Moreover, systems with multivalent presentation of mannose groups on an adequate scaffold and the specific targeting of mannose-capped dendrimers to mannose receptors, highly expressed in cells of the immune system, can be considered as

potential antiviral drugs to inhibit the DC-SIGN binding of the different virus type like HIV.⁷ Large number of dendrimers with mannose moiety has been synthesized.⁸ However in our knowledge, there are few examples of carbosilane dendrimers functionalized with mannose groups.^{5e,9}

Carbosilane dendrimers are effective scaffolds for therapeutic usefulness.¹⁰ This type of dendrimers seems to be attractive systems for manufacturing a therapeutic reagent, due to their own characteristics, such as (a) simplicity of the synthetic process to extend the generation, (b) present a hydrophobic nature in contrast to more hydrophilic polyamine-type dendrimers, (c) chemical and biochemical stability and (d) biological inertness.¹¹ Carbosilanes dendrimers bearing saccharide epitopes on the surface were first introduced by Matsuoka et al.¹² When the saccharide is mannose, Matsuoka et al.^{5d} prepared carbosilane dendrimers by nucleophilic displacement of a bromine leaving group on the dendritic molecule with a thio nucleophile borne by the sugaring structure. However, only one case of glycoconjugating carbosilane dendrimers with mannose moiety has been synthesized via a hydrosilylation reaction between di-isopropylidene protected allyl mannoside and carbosilane dendrimers with dihydrosilane surface groups and reported by Lindhorst and Boysen.⁹ In this case the hydrosilylation reaction with dendrimers containing di- or trihydrosilanes end groups and different alkenes was unfavorable,¹³ affording glycodendrimers in poor yield.

* Corresponding authors. Tel.: +34 91 8854677; fax: +34 91 8854683; e-mail addresses: paula.ortega@uah.es, mmunoz@cbm.uam.es, rafael.gomez@uah.es.

In this manuscript, we described in detail the systematic synthesis and characterization of globular carbosilane dendrimers with mannose groups in the periphery via hydrosilylation of allyl tetraacetylmannose with a carbosilane dendrimers containing monohydrosilane end groups. We also present preliminary results of their biocompatibility studies.

2. Results and discussion

2.1. Synthesis and structural characterization of carbosilane dendrimers having peripheral mannose

Preparative details and spectroscopic data for the new compounds are given in the Experimental Section. Only selected data will be presented for this discussion. Glycodendrimers formed by hydrosilylation with carbosilane dendrimers of type G_n-H_x ($n=1, 2, 3$; $x=4, 8, 16$) where 'n' means the number of generation (G) and 'x' denotes the number of branches and hence the number of peripheral groups, were synthesized as reported previously¹⁴ while the allyl tetraacetylmannose ligand (**1**) was obtained through the treatment of penta-*O*-acetylmannopyranose with allyl alcohol in the presence of boron trifluoride diethyl ether complex.^{12a,15}


The reactions were performed in ampoules with J Young valves using toluene as solvent and the Karstedt's catalyst¹⁶ and heating the mixture at 70 °C for 8 h to afford the corresponding dendrimers $G_n-[Man(OAc)]_x$ ($n=1, x=4$ (**1**); $n=2, x=8$ (**2**); $n=3, x=16$ (**3**)) in good yields as pale yellow oils (see Scheme 1 (a)). All these derivatives are soluble in common organic solvents. ¹H NMR spectroscopy was used to follow the progress of the reactions by monitoring the loss of the Si–H and the characteristic resonance of the allyl group of compound **1**. The processes occurred exclusively by β -hydrosilylation to give the Man–OCH₂CH₂CH₂Si group, and not α -hydrosilylation was observed.

In order to obtain the deacetylated dendrimers, the $G_n-[Man(OAc)]_x$ compounds were treated under argon atmosphere with a solution of NaOMe in MeOH. The resulting solution was stirred at room temperature during 2 h. After the reaction, Amberlite IR-120

was added to neutralize the reaction solution for 12 h. The suspension was filtrated and evaporated, affording a residue that was purified by column size chromatography (see Scheme 1 (b)). Dendrimers $G_n-[Man]_x$ ($n=1, x=4$ (**4**); $n=2, x=8$ (**5**); $n=3, x=16$ (**6**)) were obtained as a pale yellow solid in good yields. This family of dendrimers is soluble in THF, MeOH, and DMSO and insoluble in water. In this case, the reaction was followed by ¹³C NMR spectroscopy, through the extinction of the carbonyl resonances of acetate groups.

Structural characterization of dendrimers **1–6** has been carried out using elemental analysis, ¹H, ¹³C, and ²⁹Si NMR spectroscopy and mass spectrometry. The NMR spectroscopic and analytical data for derivatives **1–6** are consistent with their proposed structures (for some examples see Fig. 1).

¹H NMR spectra in CDCl₃ showed for the carbosilane framework of dendrimers **1–3** almost identical chemical shifts for analogous nuclei in different generations. The tetraacetylmannose unit presents five sets of signals. For H-3, H-4, and H-2 a multiplet around $\delta=5.25$ ppm is observed while for H-5 another multiplet is located at $\delta=3.98$ ppm. A broad singlet is observed for H-1 at 4.78 ppm and the signals centered at $\delta=4.24$ ppm are assigned to H6a and H6b. The acetylated groups show four resonances between $\delta=2.12$ and 1.99 ppm. Respecting to the methylene groups of the carbosilane skeleton five sets of resonances are observed with the expected integration ratio. The hydrogen atoms of the methylene group bonded to oxygen, Man–OCH₂CH₂CH₂Si, exhibit two multiplets at 3.58 and 3.38 ppm as a result of their different chemical environment. The central methylenes of SiCH₂CH₂CH₂Si and Man–OCH₂CH₂CH₂Si branches are located at $\delta=1.22$ and 1.57 ppm, whilst the methylene groups bond directly to silicon atoms are centered at $\delta=0.55$ (SiCH₂CH₂CH₂Si) and 0.42 ppm (Man–OCH₂CH₂CH₂Si). The latter assignment is based on the enlargement of the signal intensity of the resonance at $\delta=0.55$ ppm on increasing dendrimer generation. ¹³C{¹H} NMR spectra show four resonances between 170.0 and 168.0 ppm attributed to the carbonyl group of the acetylated units, the C-1 resonance appear at 97.5 ppm and the carbon atom of the methylene group bonded to –OMan give a resonance at



Scheme 1. Synthesis of globular carbosilane dendrimers with mannose groups at the periphery.




Figure 1. Molecular representation of G_2 -[Man(OAc)]₈ (**2**) and G_3 -[Man]₁₆ (**6**).

68.5 ppm while the chemical shift of the carbon atom bonded to Si in the fragment Man–OCH₂CH₂CH₂Si appears around 11.2 ppm. The ²⁹Si chemical shifts of these dendrimers have been determined by a 2D {¹H–²⁹Si}-HMBC experiment, where the outermost Si atom appears at 2.1 ppm and for the subsequent inner silicon atom around 1.0 ppm (Fig. 2).

In the deacetylated derivatives, the ¹H NMR spectra of the dendrimers **4–6** were recorded in DMSO-*d*₆ at room temperature, although in this solvent the line widths of these spectra tended to be broader than those of derivatives soluble in common organic solvents. The spectra show that the carbosilane framework is insignificantly affected by the deacetylation reaction. A broad multiplet for all the protons of mannose group between δ =4.00 and 3.20 ppm and a broad singlet centered at δ =4.56 ppm for H-1 are observed. In ¹³C{¹H} NMR spectra, the most important fact is the disappearance of the signals attributed to the carbonyl groups of acetylated units.

Dendrimers were also analyzed by mass spectroscopy (MALDI-TOF MS) using 1,8,9-trihydroxyanthracene (dithranol) as a matrix. Very clean MALDI-TOF spectra were obtained for the G_1 glyco-dendrimers, with fine peaks centered at *m/z* values matching those for the calculated sodium adducts (see Experimental section). However, for the second and third generations the molecular peaks were not observed because the dendrimers fly with more difficulty in MALDI-TOF MS and the spectra obtained showed a broader peak, as well as some fragmentation.

2.2. Dendrimer toxicity

The dendrimers **4–6** were tested on dendritic cells (from healthy donors) as an initial screen for biocompatibility. Dendritic cells (DC) are the first line of defense against HIV-1 infections and undergo maturation during virus infection and thereby become potent stimulators of cell-mediated immunity.¹⁷ The toxicity evaluation for **4–6** has been carried out by means of MTT assay. Due to the low solubility of all these systems in water, small quantities of DMSO (less than 2.5% in water, e.g., 0.5% for G_1 , 1.0% for G_2 , and 1.5% for G_3) were added, where no visual aggregation was observed, resulting in clear solutions for the cytotoxicity studies. At this DMSO

concentration the cell bioavailability is not affected. Figure 3A shows that up to 10 μ M concentration mitochondrial activity at 24 h was above 80–90% suggesting that G_1 -[Man]₄, G_2 -[Man]₈, and G_3 -[Man]₁₆ were not toxic at that concentration in both immature and mature DC (Fig. 3A), while at 20 μ M the mitochondrial activity decrease 30–35%. The MTT assay at 48 h shows the same results (Fig. 3B).

3. Conclusion

A synthetic strategy has been developed for introducing mannose groups on the periphery of spherical carbosilane dendrimers in good yields via hydrosilylation of allyl tetraacetylmannose with carbosilane dendrimers containing monohydrosilane end groups and the subsequent deacetylation reaction.

The lack of toxicity obtained, both in immature and mature dendritic cells by the different dendrimer generations with mannose groups at the periphery, shows that the new glycodendrimers can be good candidates as antiviral drugs to interact with lectin receptors like DC-SIGN.

4. Experimental section

4.1. General remarks

All manipulations of oxygen- or water-sensitive compounds were carried out under an atmosphere of argon using standard Schlenk techniques. Toluene solvent was dried and freshly distilled under argon prior to use sodium, unless otherwise stated, reagents were obtained from commercial sources and used as received. The carbosilane dendrimers of different generations nG–H_x were prepared according to reported methods.¹⁴ ¹H, ¹³C, and ²⁹Si NMR spectra were recorded on Varian Unity VXR-300 and Varian 500 Plus Instruments. Chemical shifts (δ , ppm) were measured relative to residual ¹H, ¹³C, and ²⁹Si NMR resonances for CDCl₃ and DMSO-*d*₆, used as solvents. C, H analyses were carried out with a Perkin–Elmer 240 C microanalyzer. MALDI-TOF MS samples were prepared in a 1,8,9-trihydroxyanthracene (dithranol) matrix, and spectra were recorded on a Bruker Reflex II spectrometer equipped with




Figure 2. ^1H NMR (A) and ^{13}C NMR (B) of acetylated dendrimer **2** in CDCl_3 as a solvent. ^{13}C NMR (C) of deacetylated dendrimer **5** in $\text{DMSO-}d_6$ as a solvent.

a nitrogen laser emitting at 337 nm and operated in the reflection mode at an accelerating voltage in the range 23–25 kV.

4.1.1. Synthesis of $\text{G}_1\text{-[Man(OAc)]}_4$ (1). The compound **1** (0.45 g, 1.17 mmol) and two drops of Karstedt's catalyst were added to a solution of first-generation hydrogen-terminated dendrimer $\text{G}_1\text{-H}_4$ (0.12 g, 0.29 mmol) in toluene (10 mL). The reaction mixture was heated at 70°C for one night and then evaporated to dryness to remove the solvent to give **1** as a pale yellow oil (0.50 g, 87%). ^1H NMR (CDCl_3): δ =5.31–5.21 (m, 3H, H-3, H-4, and H-2); 4.78 (br s, 1H, H-1); 4.24 (m, 2H, H-6a, and H-6b); 3.98 (m, 1H, H-5); 3.58 (m, 1H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 3.38 (m, 1H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 2.13, 2.08, 2.02, and 1.97 (s, 12H, $\text{CH}_3(\text{OAc})$); 1.54 (m, 2H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 1.28 (m, 2H, $\text{SiCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 0.55 (m, 4H, $\text{SiCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 0.45 (m, 2H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); -0.04 (s, 6H, SiMe_2). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3): 170.6, 170.0, 169.9, 169.7 (CO (OAc)); 97.5 (C-1); 71.3 (C-2); 69.7 (C-3); 69.1 (C-5); 68.3 ($\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 66.2 (C-4); 62.4 (C-6); 23.7 ($\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$);

20.9–20.7 (CH_3 (OAc)); 20.0, 18.5, 17.5 ($\text{SiCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 11.2 ($\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); -3.4 (SiMe_2). $^{29}\text{Si}\{^1\text{H}\}$ NMR (CDCl_3): 0.9 ($\text{G}_0\text{-Si}$); 2.2 ($\text{G}_1\text{-Si}$). Elemental analysis calcd (%) for $\text{C}_{88}\text{H}_{148}\text{O}_{40}\text{Si}_5$: C 53.21, H 7.51; found C 53.01, H 7.44. MALDI-TOF: $[\text{M}+\text{Na}^+]=2008.9$ uma (calcd=2008.8 uma).

4.1.2. Synthesis of $\text{G}_2\text{-[Man(OAc)]}_8$ (2). This dendrimer was prepared using a similar method to that described for **1**, starting from $\text{G}_2\text{-H}_8$ (0.17 g, 0.14 mmol), compound **1** (0.45 g, 1.16 mmol) and two drops of Karstedt's catalyst to obtain compound **2** as a pale yellow oil (0.48 g, 78%). ^1H NMR (CDCl_3): δ =5.31–5.22 (m, 6H, H-3, H-4, and H-2); 4.79 (br s, 2H, H-1); 4.25 (m, 4H, H-6a, and H-6b); 3.98 (m, 2H, H-5); 3.59 (m, 2H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 3.39 (m, 2H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 2.13, 2.08, 2.02, and 1.97 (s, 24H, $\text{CH}_3(\text{OAc})$); 1.55 (m, 4H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 1.28 (m, 6H, $\text{SiCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 0.54 (m, 12H, $\text{SiCH}_2\text{CH}_2\text{CH}_2\text{Si}$); 0.46 (m, 4H, $\text{Man-OCH}_2\text{CH}_2\text{CH}_2\text{Si}$); -0.04 (s, 12H, SiMe_2); -0.10 (s, 3H, SiMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3): 170.6, 170.1, 169.9, 169.7 (CO (OAc)); 97.5 (C-1); 71.3 (C-2); 69.7 (C-3); 69.1




Figure 3. MTT assay of dendrimers **4–6** in immature DC and mature DC (A) after 24 h (B) after 48 h. The graphic represents the media of three independent experiments.

(C-5); 68.3 (Man–OCH₂CH₂CH₂Si); 66.2 (C-4); 62.4 (C-6); 23.8 (Man–OCH₂CH₂CH₂Si); 20.9–20.7 (CH₃ (OAc)); 20.0–17.9 (SiCH₂CH₂CH₂Si); 11.2 (Man–OCH₂CH₂CH₂Si); –3.4 (SiMe₂); –5.0 (SiMe). ²⁹Si{¹H} NMR(CDCl₃): 0.9 (G₀–Si); 1.1 (G₁–Si); 2.2 (G₂–Si). Elemental analysis calcd (%) for C₁₉₂H₃₃₂O₈₀Si₁₃: C 53.81, H 7.31; found C 52.67, H 7.15.

4.1.3. Synthesis of G₃–[Man(OAc)]₁₆ (3**).** This dendrimer was prepared using a similar method to that described for **1**, starting from G₃–H₁₆ (0.14 g, 0.05 mmol), compound **1** (0.32 g, 8.32 mmol) and two drops of Karstedt's catalyst to obtain compound **3** as a pale yellow oil (0.26 g, 56%). ¹H NMR (CDCl₃): δ=5.33–5.20 (m, 12H, H-3, H-4, and H-2); 4.79 (br s, 4H, H-1); 4.26 (m, 8H, H-6a, and H-6b); 3.98 (m, 4H, H-5); 3.58 (m, 4H, Man–OCH₂CH₂CH₂Si); 3.38 (m, 4H, Man–OCH₂CH₂CH₂Si); 2.13, 2.07, 2.02, and 1.97 (s, 48H, CH₃(OAc)); 1.58 (m, 8H, Man–OCH₂CH₂CH₂Si); 1.28 (m, 14H, SiCH₂CH₂CH₂Si); 0.54 (m, 28H, SiCH₂CH₂CH₂Si); 0.45 (m, 8H, Man–OCH₂CH₂CH₂Si); –0.04 (s, 24H, SiMe₂); –0.10 (s, 9H, SiMe). ¹³C{¹H} NMR(CDCl₃): 170.6, 170.0, 169.9, 169.7 (CO (OAc)); 97.5 (C-1); 71.3 (C-2); 69.7 (C-3); 69.1 (C-5); 68.3 (Man–OCH₂CH₂CH₂Si); 66.2 (C-4); 62.4 (C-6); 23.7 (Man–OCH₂CH₂CH₂Si); 20.9–20.7 (CH₃ (OAc)); 20.0–17.9 (SiCH₂CH₂CH₂Si); 11.2 (Man–OCH₂CH₂CH₂Si); –3.4 (SiMe₂); –4.9 (SiMe). ²⁹Si{¹H}–NMR (CDCl₃): 0.9 (G₀–Si); 1.1 (overlapped signals of G₁–Si and G₂–Si); 2.2 (G₃–Si). Elemental analysis calcd (%) for C₄₀₀H₇₀₀O₁₆₀Si₂₉: C 54.08, H 7.94; found C 53.25, H 7.56.

4.1.4. Synthesis of G₁–[Man]₄ (4**).** Over a methanolic solution of glycodendrimer **1** (0.19 g, 0.09 mmol) was added 0.01 g of NaOMe dissolved in 2 mL of MeOH. The resulting solution was stirred at room temperature for 1 h 30 min and then was neutralized with Amberlite IR-120 one night; filtered, and evaporated, affording a residue that was purified by column size chromatography. The dendrimer **4** was obtained as a pale yellow solid (0.07 g; 56%). ¹H NMR (DMSO-*d*₆): δ=4.56 (br s, 1H, H-1); 3.99–3.21 (m, 8H, H-3, H-4, H-2, H-5; H-6, and Man–OCH₂CH₂CH₂Si); 1.43 (m, 2H, Man–OCH₂CH₂CH₂Si); 1.29 (m, 2H, SiCH₂CH₂CH₂Si); 0.52 (m, 4H, SiCH₂CH₂CH₂Si); 0.43 (m, 2H, Man–OCH₂CH₂CH₂Si); –0.06 (s, 6H,

SiMe₂). ¹³C{¹H}–NMR (DMSO-*d*₆): 99.2 (C-1); 73.3 (C-2); 70.5 (C-3); 69.9 (C-5); 68.6 (Man–OCH₂CH₂CH₂Si); 66.4 (C-4); 60.6 (C-6); 23.1 (Man–OCH₂CH₂CH₂Si); 18.9, 17.7, 16.4 (SiCH₂CH₂CH₂Si); 10.5 (Man–OCH₂CH₂CH₂Si); –3.9 (SiMe₂). ²⁹Si{¹H} NMR (DMSO-*d*₆): 1.0 (G₀–Si); 2.4 (G₁–Si). Elemental analysis calcd (%) for C₅₆H₁₁₆O₂₄Si₅: C 51.19, H 8.90; found C 49.92, H 8.36. MALDI-TOF: [M+Na⁺]=1335.7 uma (calcd=1335.7 uma).

4.1.5. Synthesis of G₂–[Man]₈ (5**).** This second-generation dendrimer was prepared using a similar method to that described for **4**, starting from **2** (0.21 g; 0.05 mmol) and 0.01 g of NaOMe dissolved in 2 mL of MeOH. Compound **5** was isolated as a pale yellow solid (0.09 g, 60%). ¹H NMR (DMSO-*d*₆): δ=4.56 (br s, 2H, H-1); 4.08–3.21 (m, 24H, H-3, H-4, H-2, H-5; H-6, and Man–OCH₂CH₂CH₂Si); 1.45 (m, 4H, Man–OCH₂CH₂CH₂Si); 1.29 (m, 6H, SiCH₂CH₂CH₂Si); 0.52 (m, 16H, SiCH₂CH₂CH₂Si, and Man–OCH₂CH₂CH₂Si); –0.07 (s, 15H, SiMe₂, and SiMe). ¹³C{¹H} NMR(DMSO-*d*₆): 99.2 (C-1); 73.2 (C-2); 70.5 (C-3); 69.8 (C-5); 68.6 (Man–OCH₂CH₂CH₂Si); 66.4 (C-4); 60.9 (C-6); 23.1 (Man–OCH₂CH₂CH₂Si); 18.8–16.4 (SiCH₂CH₂CH₂Si); 10.4 (Man–OCH₂CH₂CH₂Si); –3.9 (SiMe₂); –5.4 (SiMe). ²⁹Si{¹H} NMR(DMSO-*d*₆): G₀ not observed, 0.9 (G₁–Si); 2.3 (G₂–Si). Elemental analysis calcd (%) for C₁₂₈H₂₆₈O₄₈Si₁₃: C 52.28, H 9.19; found C 51.59, H 8.63.

4.1.6. Synthesis of G₃–[Man]₄ (6**).** This dendrimer was prepared using a similar method to that described for **4**, starting from **3** (0.18 g; 0.02 mmol) and 0.01 g of NaOMe dissolved in 2 mL of MeOH. Compound **6** was isolated as a pale yellow solid (0.07 g, 55%). ¹H NMR (DMSO-*d*₆): δ=4.56 (br s, 4H, H-1); 4.08–3.25 (m, 32H, H-3, H-4, H-2, H-5; H-6, Man–OCH₂CH₂CH₂Si); 1.45 (m, 8H, Man–OCH₂CH₂CH₂Si); 1.29 (m, 14H, SiCH₂CH₂CH₂Si); 0.52 (m, 30H, SiCH₂CH₂CH₂Si, and Man–OCH₂CH₂CH₂Si); –0.07 (s, 33H, SiMe₂ and SiMe). ¹³C{¹H} NMR(DMSO-*d*₆): 99.3 (C-1); 73.1 (C-2); 70.5 (C-3); 69.9 (C-5); 68.7 (Man–OCH₂CH₂CH₂Si); 66.3 (C-4); 60.6 (C-6); 23.1 (Man–OCH₂CH₂CH₂Si); 18.9–16.4 (SiCH₂CH₂CH₂Si); 10.5 (Man–OCH₂CH₂CH₂Si); –3.9 (SiMe₂); –5.5 (SiMe). ²⁹Si{¹H} NMR (DMSO-*d*₆): G₀–Si and G₁–Si not observed, 0.9 (G₂–Si); 2.2

(G₃-Si). Elemental analysis calcd (%) for C₂₇₂H₅₇₂O₉₆Si₂₉: C 52.74, H 9.31; found C 51.99, H 9.01.

4.2. Biocompatibility studies

Dendritic cells (DC) were obtained using the following procedure. Monocytes were separated from the leukophoresed blood with anti-human CD14 monoclonal antibody (mAb)-coated MicroBeads using MACS single-use separation columns (Miltenyi Biotec, Germany). Purified monocytes were suspended in RPMI 1640 medium (Sigma, US) containing 5% heat-inactivated fetal calf serum, 100 U/ml penicillin G, and 100 µg/ml streptomycin (Sigma). Monocytes obtained from one donor were plated in a flat-bottomed 6-well tissue culture plate (2×10⁶/well) and cultured with 50 ng/ml rh GM-CSF or 20 ng/ml rh IL-4 (ImmunoTools, Germany) at conditions stated above. Cells, fresh culture medium containing rh GM-CSF and rh IL-4 is added to the immature DC (iDC) culture every two days. iDC were matured by 20 ng/ml LPS (Sigma, Z) for the last two days. iDC and mDC were tested for immature or mature markers by FACS (EPICS MX-MCL, Beckman Coulter, US) and analyzed by CXP Software (Beckman Coulter).

4.3. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay

This method was selected to analyze detrimental intracellular effects on mitochondria and metabolic activity. MT-2 cells were seeded in 96 well plates in OPTIMEM[®] I medium containing 5% FBS (100×10⁵ cells in 200 µl/well) and submitted to 5, 10, and 20 µM treatment with G₁-[Man]₄, G₂-[Man]₈, and G₃-[Man]₁₆. After 20 h, 20 µl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide) substrate solution (5 mg/ml) was added to the cells to measure mitochondrial activity. After 4 h, the supernatant was removed and the formed crystals were dissolved in 200 µl DMSO and absorbance was measured at 550 nm with a reference of 690 nm. All points were performed in triplicate.

Acknowledgements

This work has been supported by grants from Fondo de Investigación Sanitaria (FIS) of Ministerio de Ciencia e Innovación FIS (PI052476, PI061479); Fundación para la Investigación y la Prevención del SIDA en España (FIPSE 24632/07); MNT-ERA NET 2007 (ref. NAN2007-31198-E), Red RIS RD06-0006-0035; Fundación Caja Navarra and Comunidad de Madrid (S-SAL-0159-2006) to MAMF and MNT-ERA NET 2007 (ref. NAN2007-31135-E) and Fondo de Investigación Sanitaria (PI080222) to UA.

References and notes

- (a) Lis, H.; Sharon, N. *Chem. Rev.* **1998**, *98*, 637–674; (b) Bovin, N. V.; Gabius, H. J. *Chem. Soc. Rev.* **1995**, *24*, 413–421; (c) Sharon, N.; Lis, H. *Sci. Am.* **1993**, *82*–89; (d) Lee, Y. C.; Lee, R. T. *Acc. Chem. Res.* **1995**, *28*, 321–327; (e) Dwek, R. A. *Chem. Rev.* **1996**, *96*, 683–720; (f) Gabius, H. J. *Eur. J. Biochem.* **1997**, *243*, 543–576; (g) Karlsson, K. A. *Biochem. Soc. Trans.* **1999**, *27*, 471–474; (h) Smith, A. E.; Helenius, A. *Science* **2004**, *304*, 237–242; (i) Angata, T.; Varki, A. *Chem. Rev.* **2002**, *102*, 439–470.
- (a) Cloninger, M. J. *Mol. Recognit. Polym.* **2008**, *335*–358; (b) Hadad, C.; Majoral, J.-P.; Muzart, J.; Caminade, M.; Bouquillon, S. *Tetrahedron Lett.* **2009**, *50*, 1902–1905; (c) Kantchev, E. A. B.; Bader, S. J.; Parquette, J. R. *Tetrahedron* **2005**, *61*, 8329–8338; (d) Han, S.; Baigude, H.; Hattori, K.; Yoshida, T.; Uryu, T. *Carbohydr. Polym.* **2007**, *68*, 26–34; (e) Turnbull, W. B.; Stoddart, J. F. *Rev. Mol. Biotechnol.* **2002**, *90*, 231–255; (f) Elsner, K.; Boysen, M. M. K.; Lindhorst, T. K. *Carbohydr. Res.* **2007**, *342*, 1715–1725.
- Specker, D.; Wittman, V. *Top. Curr. Chem.* **2007**, *267*, 65–107.
- (a) Chabre, Y. M.; Roy, R. *Curr. Top. Med. Chem.* **2008**, *8*, 1237–1285; (b) Heegaard, P. M. H.; Boas, U. *Recent Pat. Antinf. Drug Discov.* **2006**, *1*, 331–351; (c) Li, Y.; Cheng, Y.; Xu, T. *Curr. Drug Discov. Technol.* **2007**, *4*, 246–254; (d) Niederhafner, P.; Sebestik, J.; Jezek, J. *Glycopeptide dendrimers. Part I. J. Pept. Sci.* **2008**, *14*, 2–43; (e) Niederhafner, P.; Sebestik, J.; Jezek, J. *Glycopeptide dendrimers. Part II. J. Pept. Sci.* **2008**, *14*, 44–65; (f) Niederhafner, P.; Reinis, M. J.; Jezek, J. *Glycopeptide dendrimers, Part III. J. Pept. Sci.* **2008**, *14*, 556–587.
- (a) Oka, H.; Onaga, T.; Koyama, T.; Guo, C. T.; Suzuki, Y.; Esumi, Y.; Hatano, K.; Terunuma, D.; Matsuoka, K. *Bioorg. Med. Chem.* **2009**, *17*, 5465–5475; (b) Miyagawa, A.; Kurosawa, H.; Watanabe, T.; Koyama, T.; Terunuma, D.; Matsuoka, K. *Carbohydr. Polym.* **2004**, *57*, 441–450; (c) Kitov, P. I.; Sadowska, J. M.; Mulvey, G.; Armstrong, G. D.; Ling, H.; Pannu, N. S.; Read, R. J.; Bundle, D. R. *Nature* **2000**, *403*, 669–672; (d) Nishida, Y.; Dohi, H.; Uzawa, H.; Kobayashi, K. *Tetrahedron Lett.* **1998**, *39*, 8681–8684; (e) Mori, T.; Hatano, K.; Matsuoka, Y. E.; Toone, E. J.; Terunuma, D. *Tetrahedron* **2005**, *61*, 2751–2760; (f) Matsuoka, Y. E.; Kurosawa, H.; Esumi, Y.; Terunuma, D.; Kuzuhara, H. *Carbohydr. Res.* **2000**, *329*, 725–772.
- (a) Yamada, A.; Hatano, K.; Koyama, T.; Matsuoka, K.; Takahashi, N.; Hidari, K. I. P. J.; Suzuki, T.; Suzuki, Y.; Terunuma, D. *Bioorg. Med. Chem.* **2007**, *15*, 1606–1614; (b) Yamada, A.; Hatano, K. K.; Koyama, T.; Matsuoka, K.; Esumi, Y.; Koshino, H.; Hino, K.; Nishikawa, K.; Natori, Y.; Terunuma, D. *Tetrahedron* **2006**, *62*, 5074–5083; (c) Nishikawa, K.; Matsuoka, K.; Kita, E.; Okabe, N.; Mizuguchi, M.; Hino, K.; Miyazawa, S.; Yamasaki, C.; Aoki, J.; Takashima, S.; Yamakawa, Y.; Nishijima, M.; Terunuma, D.; Kuzuhara, H.; Natori, Y. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 7669–7674; (d) Watanabe, M.; Matsuoka, K.; Kita, E.; Igai, K.; Higashi, N.; Miyagawa, A.; Watanabe, T.; Yanoshita, R.; Samejima, Y.; Terunuma, D.; Natori, Y.; Nishikawa, K. *J. Infect. Dis.* **2004**, *189*, 360–368; (e) Mulvey, G. L.; Marcato, P.; Kitov, P. I.; Sadowska, J.; Bundle, D. R.; Armstrong, G. D. *J. Infect. Dis.* **2003**, *187*, 640–649; (f) Fukuda, T.; Onogita, S.; Miura, Y. *Thin Solid Films* **2009**, *518*, 880–888.
- (a) Tabarani, G.; Reina, J. J.; Ebel, C.; Vives, C.; Lortat-Jach, H.; Rojo, J.; Fieschi, F. *FEBS Lett.* **2006**, *580*, 2402–2408; (b) Baigude, H.; Katsuraya, K.; Okuyama, K.; Uryu, T. *Macromol. Chem. Phys.* **2004**, *205*, 684–691; (c) Geijtenbeek, T. B. H.; van Vliet, S. J.; van Duinshoven, G. C. F.; Figdora, C. G.; van Kooyk, Y. *Placenta* **2001**, *22*, S19–S23.
- (a) Chabre, Y. M.; Contino-Pépin, C.; Placide, V.; Shiao, T. C.; Roy, R. *J. Org. Chem.* **2008**, *73*, 5602–5605; (b) Greatrex, B. W.; Brodie, S. J.; Furneaux, R. H.; Hook, S. M.; McBurney, W. T.; Painter, G. F.; Rades, T.; Rendle, P. M. *Tetrahedron* **2009**, *65*, 2939–2950; (c) Hayes, W.; Osborn, H. M. I.; Osborn, S. D.; Rastall, R. A.; Romagnoli, B. *Tetrahedron* **2003**, *59*, 7983–7996; (d) Page, D.; Roy, R. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1765–1770; (e) Touaibia, M.; Roy, R. *J. Org. Chem.* **2008**, *73*, 9292–9302; (f) Woller, E. K.; Walter, E. D.; Morgan, J. R.; Singel, D. J.; Cloninger, M. J. *J. Am. Chem. Soc.* **2003**, *125*, 8820–8826; (g) Fernandez-Megia, E.; Correa, J.; Riguera, R. *Biomacromol.* **2006**, *7*, 3104–3111.
- Boysen, M. M. K.; Lindhorst, T. K. *Tetrahedron* **2003**, *59*, 3895–3898.
- (a) Ortega, P.; Bermejo, J. F.; Chonco, L.; de Jesús, E.; de la Mata, F. J.; Fernández, G.; Flores, J. C.; Gómez, R.; Serramía, M. J.; Muñoz-Fernández, M. A. *Eur. J. Inorg. Chem.* **2006**, 1388; (b) Bermejo, J. F.; Ortega, P.; Chonco, L.; Eritja, R.; Samaniego, R.; Müllner, M.; Fernández, G.; Flores, J. C.; Gómez, R.; Serramía, M. J.; Muñoz-Fernández, M. A. *Chem.—Eur. J.* **2007**, *13*, 483–495; (c) Weber, N.; Ortega, P.; Clemente, M. I.; Shcharbin, D.; Bryszewska, M.; de la Mata, F. J.; Gómez, R.; Muñoz-Fernández, M. A. *J. Controlled Release* **2008**, *132*, 55–64.
- van der Made, A. W.; Leeuwen, P. W. N. M. *J. Chem. Soc., Chem. Commun.* **1992**, 1400–1401.
- (a) Matsuoka, K.; Terabatake, M.; Esumi, Y.; Terunuma, D.; Kuzuhara, H. *Tetrahedron Lett.* **1999**, *40*, 7839–7842; (b) Matsuoka, K.; Kurosawa, H.; Esumi, Y.; Terunuma, D.; Kuzuhara, H. *Carbohydr. Res.* **2000**, *329*, 765–772; (c) Matsuoka, K.; Oka, H.; Koyama, T.; Esumi, Y.; Terunuma, D. *Tetrahedron Lett.* **2001**, *42*, 3327–3330.
- Omotowa, B. A.; Keefer, K. D.; Kirchmeier, R. L.; Shreeve, J. M. *J. Am. Soc.* **1999**, *121*, 11130–11138.
- (a) Seyferth, D.; Son, D. Y.; Rheingold, A. L.; Ostrander, R. L. *Organometallics* **1994**, *13*, 2682–2690; (b) Cuadrado, I.; MorGn, M.; Losada, J.; Casado, C. M.; Pascual, C.; Alonso, B.; Lobete, F. In *Advances in Dendritic Macromolecules*; Newkome, G. R., Ed.; JAI: Greenwich, CT, 1996; Vol. 3, pp 151–195.
- Takano, T.; Nakatsubo, F.; Murakami, K. *Carbohydr. Res.* **1990**, *203*, 341–342.
- Karstedt, B.D.U.S. Patent 3,775,452, 1973.
- Rinaldo, C. R. *J. Intern. Med.* **2009**, *265*, 138–158.